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Abstract
Background: Assessment of quality of care in patients with myocardial infarction (MI) should be based on data
that effectively enable determination of quality. With the need to simplify measurement techniques, the question
arises whether routine data can be used for this purpose. We therefore compared data from a German sickness
fund (AOK) with data from the Berlin Myocardial Infarction Registry (BMIR).
Methods: We included patients hospitalised for treatment of MI in Berlin from 2009-2011. We matched 2305
patients from AOK and BMIR by using deterministic record linkage with indirect identifiers. For matched patients
we compared the frequency in documentation between AOK and BMIR for quality assurance variables and
calculated the kappa coefficient (KC) as a measure of agreement.
Results: There was almost perfect agreement in documentation between AOK and BMIR data for matched patients
for: catheter laboratory (KC: 0.874), ST elevation MI (KC: 0.826), diabetes (KC: 0.818), percutaneous coronary intervention
(KC: 0.860) and hospital mortality (KC: 0.952). The remaining variables compared showed moderate or less than
moderate agreement (KC < 0.6), and were grouped in Category II with less frequent documentation in AOK for
risk factors and aspects of patients’ history; in Category III with more frequent documentation in AOK for comorbidities;
and in Category IV for medication at and after hospital discharge.
Conclusions: Routine data are primarily collected and defined for reimbursement purposes. Quality assurance represents
merely a secondary use. This explains why only a limited number of variables showed almost perfect agreement in
documentation between AOK and BMIR. If routine data are to be used for quality assessment, they must be constantly
monitored and further developed for this new application. Furthermore, routine data should be complemented
with registry data by well-established methods of record linkage to realistically reflect the situation – also for
those quality-associated variables not collected in routine data.
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Background
Collecting primary clinical data is still considered the
gold standard for assessing health-care quality [1]. It is,
however, an elaborate and expensive approach, especially
if reliable and valid answers must be provided for various
groups of patients with various diseases over relatively
long periods of time. In recent discussions, it has conse-
quently been argued that routine administrative data (e.g.,
claims data) may be used for quality assurance purposes if
certain methodological standards are followed [2–4]. This
could reduce costs and increase the reliability of data
collected.
However, claims data show certain drawbacks implicit in
the system if quality of care is to be assessed: i.e., they are
primarily collected for reimbursement purposes and are
only secondarily applied to assess quality of care [2, 5–7].
This situation gives rise to various consequences: e.g., ad-
ministrative data lack essential quality assessment parame-
ters [5]. They lack information essential for the patient's
prognosis, i.e., whether a disease is present on admission
(POA) or acquired in the hospital: indicators important in
adjusting for differences between patients [8–10]. They also
often show underestimation of comorbidities and risk fac-
tors unimportant for reimbursement [11–13].
In the German context there is, from a medical per-
spective, a lack of independent systematic analysis and
controlled trials on the quality of coding in hospitals
[5, 14]. It is argued that routine data should be used
cautiously for quality assurance [15], and that misclas-
sifications and non-standardized endpoints are com-
mon: a problem found not only in the German context
[14–20]. Quentin et al. suggested for MI coding among
11 European countries [21] that reimbursement trig-
gers ICD coding.
Despite these drawbacks, the use of administrative
data for assessing quality of care in Germany is becoming
more popular, quality of data is improving and various
projects assessing quality of care on the basis of adminis-
trative data have evolved in the last years [22–24].
But the following questions remain: whether German
claims data provide valid information on the quality of
care provided, under which circumstances this is feasible
and which data should be used [25]. These questions
provided the basis of our study. As carried out previously
in a French group that compared routine data on stroke
with registry data [26], we used the data of a clinical quality
assurance database (Berlin Myocardial Infarction Registry)
to validate the administrative data of a large German sick-
ness fund (AOK Nordost).
We chose acute myocardial infarction (MI) as disease en-
tity, because MI is a substantial public health burden [27]
with acknowledged guideline-based treatment strategies,
extensive coverage by public reporting [2] and a uniform
clinical data standard on acute coronary syndromes [28].
Methods
The Berlin Myocardial Infarction Registry
Our study was based on the long-term experience of the
Berlin Myocardial Infarction Registry (BMIR), which works
to improve the quality of hospital care for MI patients and
has continuously collected data on the treatment of patients
with MI since 1999 [29, 30].
All MI patients enter the registry who reach a hospital
within 24 hours after symptom onset with Type I MI, ac-
cording to the universal MI definition [31]. Specially trained
physicians collect data by using a questionnaire that in-
cludes patient baseline characteristics, diagnostic and thera-
peutic measures taken during in-hospital course of events
and discharge medication. After discharge, the question-
naires are forwarded to the BMIR Scientific Office at the
Technische Universität Berlin, where entries are double-
checked for errors and inconsistencies. To become a mem-
ber of the BMIR the hospitals have to formally agree to
include all MI patients Type I in the registry. Regular moni-
toring and peer review take place, and site audits are per-
formed to ensure that patients are consecutively included
in the registry. Patients are also selected randomly from
every institution, with source-data verification for an
average of 7.5 % of patients.
Patients’ data are collected pseudonymously. The
registry was approved by the Berlin Board for Data Privacy
Monitoring. The study protocol confirms to the ethical
guidelines of the 1975 Declaration of Helsinki.
The BMIR is a self-organised institution run by car-
diologists. Its structure promotes the internal validity of
data collected, since those interested in participating in a
voluntary registry do so out of self-interest and not out of
fear of negative consequences [32] – and it provides
clinicians a forum to communicate with each other regu-
larly and to discuss problems jointly. This approach - as
Bradley et al. were able to show - may reduce 30-day mor-
tality rates in MI [33].
AOK Nordost
In Germany, health insurance is mandatory for all citizens
and permanent residents. It is provided mainly by compet-
ing, not-for-profit, nongovernmental health insurance funds
(sickness funds) in the statutory health insurance scheme
with a uniform benefit package – and by substitutive
private health insurance for employees above an in-
come threshold, civil servants and self-employed [34].
In 2011, 86 % of the population were covered by sick-
ness funds and 13 % by private health insurance [35].
In 2011, 156 statutory sickness funds were registered in
Germany. Since 1996, patients may choose which sickness
fund they want to join. Large discrepancies exist among
the sickness funds in regard to their structure and to the
health care risks of their members. The AOK Nordost,
one of the largest German sickness funds, insured 35 % of
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all MI patients treated in Berlin in 2009 – 2011 [27]. For
historic reasons, patients insured with AOK are older,
predominantly female, and are afflicted by more comor-
bidities than among the average German population.
German sickness funds collect data for reimbursement
purposes through a system of diagnosis-related groups
(DRG) [21]. Introduction of the DRG system in the
German health care sector in 2004 – 2005 enabled for
the first time the possibility of using routine data not
only for reimbursement purposes, but also for assessing
quality of care.
For claims purposes, physicians in German hospitals
are legally obligated to code a principal diagnosis and an
unlimited number of additional comorbidities or compli-
cations, in accordance with the German Modification of
the International Classification of Diseases (10th revision).
This enabled us to use ICD-10 I21 for defining patients
with MI from the insurance data set, which reflects a diag-
nosis collected reliably in hospital settings as others were
able to show [6, 36, 37]. We used the subcategories with a
fourth character in I21.0 through I21.3. for defining pa-
tients with ST-segment elevation myocardial infarction
(STEMI), and the remaining subcategories I21.4 and I21.9
for defining patients without persistent ST-segment eleva-
tion myocardial infarction (NSTEMI). This coding respon-
sibility also enabled us to define patients’ risk factors and
comorbidities using the following codes: hypertension I10,
I11, I12, I13 or I15; smoking F17; hypercholesterolemia
E78; diabetes E10, E11, E12, E13, or E14; renal failure
N17, N18 or N19; congestive heart failure I50; atrial fibril-
lation I48.1; cardiogenic shock R57.0; stroke I60, I61, I62,
I63, I64 or G45.
Physicians must likewise code operations and interven-
tions according to the German Code for Operations and
Procedures (OPS), adapted from the WHO International
Classification of Procedures in Medicine. Percutaneous
coronary intervention (PCI) as a procedure was operation-
alized with OPS 8-837 in our study.
No data on in-hospital medication are collected in the
German system. Data on medication are routinely col-
lected only in the outpatient setting. Pharmacies are
reimbursed for the prescriptions handed out to patients.
These data are coded according to the internationally
accepted Anatomical Therapeutic Chemical Classification
System (ATC). We used the following ATC codes for our
analysis: beta-blockers as C07; ACE inhibitors and/or sar-
tans as C09A, C09B, C09C, C09D or C09X; CSE inhibi-
tors as C10AA, C10BA or C10BX; and antithrombotics as
B01AC, B01AC06, B01AC04 or B01AC.
For our study we chose only those variables from the
AOK data set that we assumed to be comparable to the
variables collected in the BMIR, and that have been used
by Freisinger et al. as well [38]. Other variables important
for quality assessment in treatment of MI patients – i.e.,
time to intervention, guideline-recommended in-hospital
medication, or smoking cessation counselling – were not
available from the AOK data set.
For the purpose of our study, AOK patients’ data were
processed pseudonymously. The Data Privacy Board of
AOK Nordost as well as the Berlin Board for Data Privacy
Monitoring agreed to the study and its design.
Patients included
In our study we included all MI patients aged ≥ 20 years
who were treated in a hospital in Berlin between 2009
and 2011. The BMIR included 9297 patients from 19
participating hospitals, of which 17 were equipped with
a cath lab. From the AOK data, patients coded with the
main diagnosis of ICD-10 code I21 were selected; they
were 8909 patients from 37 hospitals, including 20
hospitals with a cath lab.
Developing a data set for comparing documentation from
AOK and BMIR
To compare data from AOK and BMIR, we performed
various methodological steps, which are summarized in
a flow chart in Fig. 1.
1st Step: Harmonisation of case definition
In comparison of data, case definition used in both data
sets should be the same. In our first step, therefore, we
harmonised case definitions from AOK and BMIR, with
the BMIR definition as basis. The AOK system counts as
one single case a transaction for which the hospital is
remunerated, whereas the BMIR defines one patient
according to a complete illness episode, including referral,
transfer and readmission within 28 days [31]. AOK cases
belonging to the same patient with the same illness epi-
sode were combined to represent one patient by joining
them according to the point in time of treatment during
the same illness episode. We applied this procedure to
13 % of AOK cases. We were left with 7738 AOK patients
for further analysis, and with the problem of how to deal
with differences in secondary coding among the various
“single-case AOK patients”. We resolved this difficulty as
follows: a “multiple-case AOK patient” was considered as
suffering from hypertension, hypercholesterolemia, dia-
betes or stroke if any one of the single cases was coded
with the respective disease; as suffering from ST-elevation
MI or from a disease that could also be considered a com-
plication of MI (atrial fibrillation, CHF, cardiogenic shock,
or renal failure) if the chronologically initial case had the
information for the respective disease coded; and as re-
ceiving PCI as first-line treatment if PCI treatment was
coded in the chronologically initial case or in the direct-
transfer case.
Maier et al. BMC Health Services Research  (2016) 16:605 Page 3 of 9
2nd Step: Extrapolated overlap
Inclusion criteria differed for BMIR and AOK patients,
which is a common phenomenon among different data
sets, as also described by others [16, 17, 39]. To be able
to compare both data sets, we had to define a possible
overlap of patients from both data sets. Only patients
with the classic spontaneous Type I MI based on athero-
sclerotic plaque rupture were entered in the BMIR.
AOK included patients with all types of MI, since ICD-
10 coding does not correspond to the typology proposed
in the universal MI definition [31]. Type I MI, being the
classic MI, is of primary interest with reference to con-
sideration of treatment and outcome. Type II MI is con-
sidered a secondary MI with an imbalance between
myocardial oxygen supply and/or demand, independent
even of atherosclerosis. Treatment and prognosis of both
types of MI differ, and recent publications show that pa-
tients with Type II MI comprise about one-fourth of MI
patients and differ in clinical outcome [40, 41]. We
therefore had to restrict our comparison to patients with
Type I MI.
Since AOK included only patients insured by AOK
(35 % of all MI patients), and since BMIR included all
patients insured by any sickness fund or private health
insurance plan, we had to restrict our analysis again to
patients insured by AOK. Based on figures available for
Berlin [27] and on the published distribution of MI
types, we extrapolated a hypothetical overlap between
the BMIR and AOK data to include 3254 patients (cal-
culations not presented here).
3rd Step: Record linkage
In a third step, we identified by record linkage those pa-
tients from the hypothetical overlap between the two data
sets that were identical. Since data from both data sets
were pseudonymized, we applied deterministic record
linkage with 4 indirect identifiers for the linkage process
[42, 43]: date (1) and time of admission in minutes (2),
gender (3) and age (4) as key matching variables. Our aim
in linkage was to provide a data set in which documenta-
tion for identical patients in both data sets could be com-
pared, irrespective of the representativeness of the data
and of the percentage of patients successfully linked. The
record linkage process is described elsewhere [44]. We
were able to successfully link 2557 patients, from which
we had to subtract 252 patients. These were patients for
whom the registry lacked outcome data because they were
directly transferred to hospitals not participating in the
Registry. We were left with 2305 matched patients as the
basis for our comparison.
Data analysis
We compared frequencies in documentation for linked
patients from both data sets as percentages and calculated




9297 BMIR MI patients
from 19 hospitals
only type I MI
all sickness funds
baseline data
7738 AOK MI patients
one patient - one case
9297 BMIR MI patients
one patient - one case
1st step: harmoni-
sation of cases





3254 BMIR MI patients
only type I
only AOK insured
3rd step: after 
record linkage
2557 identical MI patients
in both data sets
missing 
outcome data- 252 MI patients
2305 identical MI patients
in both data sets
data basis for 
analysis
Fig. 1 Flow chart: Developing a data set for comparing documentation between AOK and BMIR
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the kappa coefficient (KC) as a measure of agreement.
A kappa coefficient < 0 was considered as no agree-
ment, 0–0.20 as slight, 0.21 – 0.40 as fair, 0.41 – 0.60
as moderate, 0.61 – 0.80 as substantial and 0.81-0.99 as
almost perfect agreement [36, 45].
Results
After case harmonisation and record linkage, we arrived
at a data set of 3205 linked patients for whom we com-
pared documentation between the AOK and the BMIR
data set.
The results showed that the relative frequencies of
documentation between the two data sets varied. Docu-
mentation for some variables was comparable: e.g.,
82 % treatment with PCI or 9.2 % in-hospital death.
Certain risk factors – e.g., hypertension with 79.9 % in
BMIR and 67.8 % in AOK, or smoking with 39.9 % in
BMIR and 14.8 % in AOK and hypercholesterolemia
with 49.5 % in BMIR and 41.8 % in AOK – were coded
more often in the BMIR data. Other comorbidities –
e.g., CHF with 39.3 % in AOK and 16.7 % in BMIR,
renal failure with 23.8 % in AOK and 20.8 % in BMIR
and atrial fibrillation with 15.5 % in AOK and 11.3 % in
BMIR – were coded more often in AOK data.
The results also showed that the measure of agreement
in documentation between AOK and BMIR ranged from
almost perfect to hardly any agreement, depending on the
variables compared: for example, 96 % of patients were
treated in a hospital with a cath lab, according to both
data sets, with a kappa coefficient of 0.902. On the other
hand, the kappa coefficient was only 0.209 for documenta-
tion of CHF (for results see Tables 1, 2 and 3).
Since we observed such patterns of differences in report-
ing, we developed four categories to group the various vari-
ables studied (see also Tables 1, 2 and 3): one category for
similar documentation in both data sets, a second category
for less frequent documentation in AOK, a third category
for more frequent documentation in AOK and a final cat-
egory for different chronological documentation between
the two data sets. Since mere frequencies are a poor meas-
ure of agreement, we extended our analysis to include the
magnitude of the kappa coefficients in our categories. Using
this approach, we arrived at the following categories:
Category I was defined as the category with data
reported at the same frequency in both data sets and
with almost perfect agreement between the two data-
sets (KC > 0.80). STEMI and diabetes as patient char-
acteristics, treatment in a hospital with a catheter
laboratory as a structural variable, treatment with PCI
as a process variable, length of stay in the hospital and
hospital mortality as outcome parameters were vari-
ables that fell into this category (Tables 1 and 2) and
were considered valid and reliable data for assessing
quality of care.
Category II was defined as the category with data
reported less frequently in the AOK compared to the
BMIR data set. This category was divided into two sub-
groups with subcategory IIa describing fair to moderate
agreement between registry and sickness fund data (KC:
0.21 - 0.60). We found classic MI risk factors: e.g.,
hypertension, hypercholesterolemia and smoking in this
category (Table 1). AOK data from this category were
considered to be requiring caution in assessing quality of
care. Subcategory IIb described hardly any agreement
between BMIR and AOK data (KC: ≤ 0.20) and included
previous diseases: e.g., previous stroke, previous MI and
previous PCI. AOK data which fell into this subcategory
were considered unusable for assessing quality of care.
Category III was defined as the category with data
reported more often in the AOK compared with the
BMIR data set. It was not necessary to form subgroups
in this category, because all variables showed fair to
moderate agreement between BMIR and AOK data (KC:
0.21 – 0.60). This category included classic MI comor-
bidities: e.g., renal failure, atrial fibrillation, congestive
heart failure and cardiogenic shock. AOK data that fell
into this subcategory were considered as requiring cau-
tion in assessing quality of care.
Category IV formed a special category on medication,
because information on medication was collected at a
different point in time in the two data sets. Category IV
showed data reported less frequently in the AOK compared
to the BMIR data set with in general documentation of a
high number of patients receiving guideline-recommended
medication in both data sets, but with a low kappa
coefficient.
Discussion
Assessing quality of health care should be based on the
most accurate measures available, since consequences of
incorrect measurements can be enormous [2]. If we
consider, for example, pay-for-performance schemes
that depend on quality of care delivered, or on hospital
rankings with public reporting, accurate data and analysis
are essential. Quality measures should also be accurate to
increase trust in the data. It is physicians and other health
personnel that must change their behaviour if quality of
care is to be improved. If data on quality of care does not
reflect the situation accurately and realistically, then
health personnel will mistrust the data, which in turn will
counteract any quality assessment initiatives [32]. When
using routine data to analyse quality of care delivered, we
therefore must be sure that these data provide a reliable,
valid and trustworthy picture of the situation.
Using routine data for assessing quality of care is not
new in the German context. What is new in our study,
to our knowledge, is our approach: We have directly
compared data from one of the largest German sickness
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funds with data from a quality registry by linking indi-
vidual patients and comparing documentation in both
data sets for exactly the same patient. This is a unique
approach with individual record linkage, which enabled
us to show that shortcomings assumed for routine data
from various settings [5–21] were confirmed in a direct
comparison for the German context.
Validity of AOK data for quality assurance
Only a limited number of variables showed a high degree
of agreement. If our results from Category I were more
generalized, one could argue that structural factors (e.g.,
availability of a catheter laboratory), process indicators as
indicated by procedures reimbursed by the sickness funds
and coded according to the OPS classification (i.e. PCI),
and hard outcome parameters (e.g., hospital mortality and
length of stay in the hospital) are routine data comparable
to data collected in the setting of a registry primary aimed
to improve quality of care in the German setting.
Apart from these variables, two other variables also
showed almost perfect agreement: STEMI (respective
NSTEMI) and diabetes. For diabetes, others have also
revealed that agreement between different data sources was
high [11]. This has important implications for risk adjust-
ment, since patients with STEMI or diabetes are acutely
and more severely ill and have a higher in-hospital death
rate than those without these diseases. The almost perfect
agreement in STEMI documentation also showed that
codes I21.0 through I21.3 may be used as an indirect meas-
ure to approximate the number of cases with STEMI in the
absence of direct measure of STEMI in routine data. This
aspect requires further study, since it may suggest a more
homogenous subgroup of MI patients that could be more
easily compared among different routine data sets [37].
Variables on classic risk factors disclosed underreport-
ing and only a fair measure of agreement in the AOK
data. Since risk factors per se do not influence reim-
bursement for acute hospital treatment of MI, the results
of our analysis were as expected and showed unreliable
coding in the sickness fund data. This is in line with the
publication by Lujic et al. and makes routine data an un-
reliable tool for consideration of risk factors [12].
Variables on patients’ history with hardly any degree of
agreement pose a special problem, possibly specific for
Table 1 Comparison of documentation of baseline characteristics of matched cases, with measurement of agreement








Age (mean) 69 yrs. -
Women 35 % -
Treatment in hospital with cath lab 96.5 % 96.6 % 0.902 I
STEMI 47.5 % 46.9 % 0.835 I
Diabetes 30.3 % 33.2 % 0.819 I
Hypertension 67.8 % 79.9 % 0.417 IIa
Smoking 14.8 % 39.9 % 0.390 IIa
Hypercholesterolemia 41.8 % 49.5 % 0.341 IIa
Previous stroke 0.9 % 9.7 % 0.103 IIb
Previous MI 3.2 % 24.8 % 0.007 IIb
Previous PCI 1.0 % 25.6 % 0.010 IIb
Atrial fibrillation 15.5 % 11.3 % 0.582 III
CHF 39.3 % 16.7 % 0.209 III
Renal failure 23.8 % 20.8 % 0.618 III
Cardiogenic shock 6.4 % 5.4 % 0.447 III
Table 2 Comparison of documentation of treatment and outcome of matched cases, with measurement of agreement









(PCI for pts. coded as STEMI in AOK and BMIR)











Hospital mortality 9.2 % 9.2 % 0.979 I
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the German context. AOK data were collected on a case
basis. To enable analysis of a patient’s medical history,
various cases from the past must be linked to constitute
one patient. This is a difficult task, since initial DRG
coding was introduced only in 2004/2005, and historical
analysis cannot extend back beyond this date. Second,
joining cases to constitute one patient over a long period
of time involves a data privacy issue not welcomed by
data privacy authorities in and outside the sickness
funds. Third, sickness funds do not have an internal in-
formation system based on patients rather than cases,
which also creates a technical problem for the sickness
funds to unite various internal sickness fund data bases.
Only limited data on patients’ history are therefore avail-
able from routine data – the farther back in time, the
more difficult it becomes to obtain reliable information
on patients’ medical history.
Variables on classic MI comorbidities that worsen pa-
tients’ prognosis and that – coded as a secondary diag-
nosis – increase the reimbursement received for the
patient were more frequently reported in the AOK data
set, which is in line with expected results. This is because, if
a diagnosis is relevant to reimbursement, it is assumed that
this increases the reliability of coding [46, 47]. At the same
time, the measure of agreement on classic MI comorbidities
between both data sets was only fair to moderate, which can
be explained by the difference in data collection. AOK data
show all secondary diagnoses regardless of whether they
were present on admission or had developed as a complica-
tion during hospital stay. BMIR data reflect only comorbidi-
ties POA necessary for adjusting for differences in patients’
mix. Without being able to differentiate between POA, sick-
ness fund data have only a limited ability to adjust for differ-
ences in patient mix [8–10] to assess of quality of care.
Since in-hospital medication is not documented in the
sickness fund data, we had designed our study to compare
discharge medication with medication in the outpatient
setting two quarters after discharge – and we had expected
results to be similar. But, as our results showed, there was a
discrepancy between hospital discharge medication and
medication after discharge, which may be attributed to the
different points in time of data collection. This also may
reflect an actual discrepancy between hospital discharge
medication and medication after discharge – as others have
also shown [48, 49]. It may also lie, however, in the fact that
sickness funds have only those data on out-patient medica-
tion that are submitted for reimbursement by a pharmacist.
Medications taken by the patients but not reimbursed do
not appear in the sickness fund data set. The kappa
coefficient may have been low (even though levels of
agreement were high), because it depends on marginal
frequencies [45, 50].
Since routine German data lack variables on quality of
care other than those described, our results prompt us
to argue that German routine data should either be
broadened to include POA indicators, time indicators
and drugs given in hospital – or should be regularly linked
with registry data to reliably assess care of MI patients in
the future.
Limitations
The reliability of the AOK data depended on the export
of data carried out within the sickness fund. Although
we carried out plausibility checks on the data and com-
pared them with other similar data, we cannot exclude
the possibility that problems in data export could have
arisen within the sickness fund. Our study design also
did not allow verification of the ICD diagnosis of I21 by
AOK data. As others have shown, however, the coding
of I21 in the hospital setting is quite reliable [6, 36, 37].
Our study was based on registry data, which have their
own drawbacks [51, 52]. Since the emphasis of our study
lay on the analysis of data after linkage, possible drawbacks
of BMIR data were of minor importance. The emphasis of
our study was on comparison of documentation in AOK
and BMIR data. With this approach, variables not available
in routine data, but important for assessing quality of care,
were not considered for our analysis (e.g., intervention time
in STEMI patients).
Our study referred to the German context and was
based on German legal aspects of diagnosis coding and
procedures that may not be applicable to other national
settings.
Conclusions
Administrative data are collected for reimbursement pur-
poses. If used for quality assessment at all, they are applied
for this purpose only secondarily, which explains a number
Table 3 Comparison of documentation for medication upon hospital discharge (BMIR) and medication over 2 quarters after
discharge (AOK), with measurement of agreement








Statins 73.2 % 90.0 % 0.281 IV
ACE inhibitors and/or sartans 76.4 % 92.3 % 0.192 IV
Beta blockers 78.3 % 95.0 % 0.166 IV
Antithrombotics 81.0 % 98.5 % 0.042 IV
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of their drawbacks. We have grouped the data in four
categories to represent the various types of agreement
or disagreement between two data sets. From these cat-
egories only those variables grouped in Category I had
an almost perfect degree of agreement between both
data sets. All other variables, especially those necessary
for risk adjustment, showed only moderate to less than
moderate agreement in documentation between the two
data sets. They are therefore not considered as reliable
tools for assessing quality of care. If routine data are to be
used for quality assessment, they must be constantly
monitored and further developed for this new applica-
tion [20, 53]: e.g., by introduction of POA indicators,
time indicators and drugs given in hospital. Furthermore,
routine data should be complemented with registry data
by well-established methods of record linkage to realistic-
ally reflect the situation – also for those quality-associated
variables not collected in routine data.
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